AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- ADVENT-AML Phase 1B trial is open for enrolment.
- The trial is open for patients with refractory/ relapsed Acute Myeloid Leukemia (AML), before opening for patients with newly diagnosed AML.
- The study is the first clinical trial to assess NK cells in conjunction with AML standard of care therapy.
Chimeric Therapeutics (ASX: CHM) informed that the enrolment has started for the Phase 1B ADVENT-AML (CHM 0201 + Azacitidine + Venetoclax) clinical trial at The University of Texas MD Anderson Cancer Center.
The enrolment has been opened for patients with refractory/relapsed Acute Myeloid Leukemia (AML), before the recruitment of around 20 patients with recently diagnosed AML.
About the trial
The trial is an investigator-initiated study that aims at assessing Chimeric’ s CHM 0201 in conjunction with standard of care therapy for patients with newly diagnosed AML. CHM 0201 is an off-the-shelf universal donor NK cell therapy.
The principal investigator of the trial is Abhishek Maiti MD. He is an assistant professor in the Department of Leukemia.
ADVENT-AML 1B study is the first trial to examine the combination oof NK cell therapy with current standard of care - Azacitidine and Venetoclax.
Data source: company update
As per the terms of clinical trial agreement with MD Anderson, the company would extend partial financial support for the trial and provide CHM 0201 study drug. In addition to the financial support from CHM, the study will get assistance through grant funding from numerous funding sources including Gateway for Cancer Research.
CHM shares traded at AU$0.030 apiece at the time of writing on 16 January 2024.
